- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Addressing Unmet Needs in the PAH Landscape
Marius Hoeper, MD, describes the role clinicians can play in advocating for health care system reforms that could address the economic implications of PAH and discusses the key unmet needs in the PAH treatment landscape.
EP: 1.Evolving Guidelines for PAH Treatment
EP: 2.New Therapeutic Frontiers in PAH
EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management
EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension
EP: 5.Breaking Down the PAH Cost Burden
EP: 6.A New Era in PAH Treatment?
EP: 7.Clinical Evidence for Emerging PAH Therapies
EP: 8.Integrating New PAH Therapies into Clinical Practice
EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes
EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension
EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH
EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches
EP: 13.Optimizing PAH Care Delivery for Better Outcomes
EP: 14.Addressing Unmet Needs in the PAH Landscape
Video content above is prompted by the following questions:
- What role can clinicians play in advocating for integrated care delivery models, value-based payment strategies, or other health care system reforms that could address the economic implications of pulmonary arterial hypertension (PAH) more effectively?
- What are the key unmet needs or challenges related to the management of PAH that you hope will be addressed more comprehensively in the coming years as the treatment landscape evolves with therapies like sotatercept?
New Study Evaluates Quality-of-Life Instruments for Patients With PAH
December 12th 2024A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that although several instruments demonstrate strong psychometric properties and reliability, significant gaps remain in these tools' validation and methodological rigor.
Read More
Nanoparticle Delivery Holds Promise for Treatment of PAH
December 8th 2024Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline (MCT) injection in rats.
Read More
